COLO B Coloplast A/S Class B

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Allocation of Share Options

Report on transactions of executives and related parties in Coloplast shares and related securities

According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities.

The below transactions concern allocation of share options.

For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:





  Details of the person discharging managerial responsibilities/person closely associated
a) Name Kristian Villumsen
2 Reason for the notification
a) Position/status President & CEO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 73,690
d) Aggregated information  
-        Aggregated volume 73,690 share options
-        Price DKK 0.00
e) Date of the transaction 2025-02-04, 12:10 UTC
f) Place of the transaction Outside a trading venue



 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Anders Lonning-Skovgaard
2 Reason for the notification
a) Position/status Executive Vice President & CFO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 37,511
d) Aggregated information  
-        Aggregated volume 37,511 share options
-        Price DKK 0.00
e) Date of the transaction 2025-02-04, 12:10 UTC
f) Place of the transaction Outside a trading venue

  

For further information, please contact

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Aleksandra Dimovska

Vice President, Investor Relations

Tel. /

Email:

Simone Dyrby Helvind

Senior Manager, Investor Relations

Tel. /

Email:

Press and media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR) no. 69749917

Website

 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.

Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-02.



All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment



EN
04/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H...

Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25 Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostomy Care. Q2 EBIT margin1 held steady at 27%. Reported revenue in DKK grew 5%, impacted by the Skin Care divestment. Organic growth rates by business area: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10% and Interventional Urology -1%.Growth in Chronic Care was driven ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch